docetaxel + fluorouracil + epirubicin + cyclophosphamide

This refers to the control arm chemotherapy regimen used in the CBCSG010 (China Breast Cancer Clinical Study Group 010) phase III clinical trial for triple-negative breast cancer. The regimen consists of sequential administration of docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide (T-FEC). Specifically, patients received 3 cycles of docetaxel (75 mg/m2) followed by 3 cycles of FEC (fluorouracil 500 mg/m2, epirubicin 75 mg/m2, and cyclophosphamide 500 mg/m2), all administered intravenously on day 1 of every 3-week cycle. This combination represents a standard adjuvant chemotherapy approach for triple-negative breast cancer, combining a taxane with an anthracycline-based regimen. The active ingredients are all cytotoxic chemotherapy agents: docetaxel stabilizes microtubules, epirubicin intercalates DNA and inhibits topoisomerase II, cyclophosphamide is an alkylating agent, and fluorouracil is an antimetabolite that inhibits thymidylate synthase.

Other names

fluorouracil + epirubicin + cyclophosphamide + docetaxel-China Breast Cancer Clinical Study Group-triple-negative breast cancersequential T-FECdocetaxel followed by FEC